The cost-effectiveness of expanding newborn screening for up to 21 inherited metabolic disorders using tandem mass spectrometry: results from a decision-analytic model.

@article{Cipriano2007TheCO,
  title={The cost-effectiveness of expanding newborn screening for up to 21 inherited metabolic disorders using tandem mass spectrometry: results from a decision-analytic model.},
  author={Lauren E. Cipriano and Charles Anthony Rupar and Gregory S. Zaric},
  journal={Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research},
  year={2007},
  volume={10 2},
  pages={83-97}
}
OBJECTIVES In 2005, in Ontario, Canada, newborns were only screened for phenylketonuria (PKU) and hypothyroidism. Tandem mass spectrometry (MS/MS) has since been implemented as a new screening technology because it can screen for PKU and many other diseases simultaneously. We estimated the cost-effectiveness of using this technology to expand the Ontario newborn screening program to screen for each disease independently and for hypothetical bundles of up to 21 metabolic diseases. METHODS We… CONTINUE READING